Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Choline Fenofibrate · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | - |
| 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Choline Fenofibrate | DRUG | 135 mg |
| Placebo | DRUG | Placebo |
Inclusion Criteria * With DME in at least one eye of the subject and this eye presenting with macula thickness ≥ 300 µm on OCT examination at baseline in at least one of the 5 following zones: center zone, or superior inner zone, or nasal inner zone, or inferior inner zone, or temporal inner zone, ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| EyePoint, Inc. | EYPT | 2 | PHASE3 | EYP-1901, Aflibercept |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE3 | Aflibercept |
| Oculis Holding AG | OCS | 2 | PHASE3 | Dexamethasone, Vehicle |
| AbbVie, Inc. | ABBV | 3 | PHASE2 | ABBV-RGX-314 Dose 1, Steroid, Aflibercept |
| Outlook Therapeutics, Inc. | OTLK | 1 | PHASE3 | bevacizumab |
| 4D Molecular Therapeutics, Inc. | FDMT | 1 | PHASE2 | 4D-150 IVT, Aflibercept IVT |
| Alvotech | ALVO | 1 | PHASE3 | AVT29, Eylea HD |
| Kiora Pharmaceuticals, Inc. | KPRX | 1 | PHASE2 | KIO-104 |
| REGENXBIO, Inc. | RGNX | 1 | PHASE2 | RGX-314 Dose 1, RGX-314 Dose 2, Aflibercept |
| Ocugen Inc | OCGN | 1 | PHASE1 | OCU200 |
| Adverum Biotechnologies, Inc. | ADVM | 1 | - | ADVM-022 |
Choline Fenofibrate is an investigational small molecule being studied for the treatment of Diabetic Macular Edema, a condition that causes vision loss in people with diabetes. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
Choline Fenofibrate is being developed by Abbott Laboratories, a company traded on the New York Stock Exchange under the ticker symbol ABT. The drug is currently in Phase 2 clinical trials for Diabetic Macular Edema.
Choline Fenofibrate is in Phase 2 clinical development. It is an investigational drug for Diabetic Macular Edema and has not received regulatory approval. One Phase 2 trial has been completed, and no active trials are currently listed.
Choline Fenofibrate has one completed Phase 2 clinical trial, identified as NCT00683176, titled "Effect of Choline Fenofibrate (SLV348) on Macular Edema." The trial enrolled 110 participants with Diabetic Macular Edema across multiple European countries, including Bulgaria, Czechia, Denmark, Germany, Hungary, Italy, Netherlands, Poland, Spain, and the United Kingdom.
Yes, Choline Fenofibrate is also known as SLV348. The clinical trial NCT00683176, which studied the drug's effect on macular edema, refers to it as SLV348. This alternative name may appear in scientific literature and trial registries.